Published in J Urol on April 01, 2007
The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell (2009) 2.22
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol (2011) 1.81
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep (2010) 1.74
Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume. BJU Int (2012) 1.52
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J Urol (2013) 1.40
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.34
Race and socioeconomic status are independently associated with benign prostatic hyperplasia. J Urol (2008) 1.22
Progression of lower urinary tract symptoms in older men: a community based study. J Urol (2010) 1.22
Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol (2012) 1.16
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
Metabolic syndrome and urologic diseases. Rev Urol (2010) 1.09
Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int (2007) 1.07
Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol (2011) 1.01
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate (2008) 1.00
Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J Urol (2011) 0.98
Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Korean J Urol (2011) 0.98
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int (2010) 0.96
A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol (2013) 0.96
Effects of obesity on prostate volume and lower urinary tract symptoms in korean men. Korean J Urol (2010) 0.94
Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol (2011) 0.91
The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome. World J Urol (2015) 0.91
Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health (2013) 0.90
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate (2009) 0.89
Holmium Laser Enucleation of the Prostate: Comparison of Immediate Postoperative Outcomes in Patients with and without Antithrombotic Therapy. Curr Urol (2013) 0.89
Incidence of lower urinary tract symptoms in a population-based study of men and women. Urology (2013) 0.88
Association between biomarkers of obesity and risk of high-grade prostatic intraepithelial neoplasia and prostate cancer--evidence of effect modification by prostate size. Cancer Lett (2012) 0.88
Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol (2012) 0.86
Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol (2014) 0.85
Impact of type 2 diabetes on lower urinary tract symptoms in men: a cohort study. BMC Urol (2013) 0.84
Association of metabolic syndrome and benign prostate enlargement in young korean males. Korean J Urol (2011) 0.84
Associations between modest weight changes and onset and progression of lower urinary tract symptoms in two population-based cohorts. Urology (2011) 0.84
Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol (2016) 0.84
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate (2010) 0.82
Lifestyle and lower urinary tract symptoms: what is the correlation in men? Curr Opin Urol (2015) 0.80
Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2012) 0.80
The impact of obesity towards prostate diseases. Prostate Int (2015) 0.80
Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting. BJU Int (2012) 0.78
Physical characteristics associated with weight misperception among overweight and obese men: NHANES 1999-2006. Obesity (Silver Spring) (2014) 0.78
The effect of metabolic syndrome upon the success of varicocelectomy. ScientificWorldJournal (2012) 0.75
Effect of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia: a randomized controlled trial. Korean J Urol (2015) 0.75
Clinical Implications of Residual Urine in Korean Benign Prostatic Hyperplasia (BPH) Patients: A Prognostic Factor for BPH-Related Clinical Events. Int Neurourol J (2010) 0.75
Association of Functional Ability and Benign Prostatic Hyperplasia With Urinary Incontinence in Older Korean Men. Int Neurourol J (2016) 0.75
Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men. Asian J Androl (2015) 0.75
Obesity inversely correlates with prostate-specific antigen levels in a population with normal screening results of prostate cancer in northwestern China. Braz J Med Biol Res (2016) 0.75
Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume. PLoS One (2015) 0.75
Obesity as a Risk Factor for Prostatic Enlargement: A Retrospective Cohort Study in Korea. Int Neurourol J (2016) 0.75
Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol (2015) 0.75
Association of variants in genes related to the immune response and obesity with BPH in CLUE II. Prostate Cancer Prostatic Dis (2014) 0.75
Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model. Prostate (2016) 0.75
Promoting Physical Activity among Underserved Populations. Curr Sports Med Rep (2016) 0.75
Effect of obesity on International Prostate Symptom Score and prostate volume. Urol Ann (2015) 0.75
The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep (2017) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake. Am J Epidemiol (2014) 2.53
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
Low-fat dietary pattern and change in body-composition traits in the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 2.43
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Protein intake and incident frailty in the Women's Health Initiative observational study. J Am Geriatr Soc (2010) 2.28
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc (2003) 2.11
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology (2013) 2.06
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05
Evaluation and comparison of food records, recalls, and frequencies for energy and protein assessment by using recovery biomarkers. Am J Epidemiol (2011) 2.04
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Dietary acculturation: applications to nutrition research and dietetics. J Am Diet Assoc (2002) 1.95
Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst (2013) 1.94
Food nutrition label use is associated with demographic, behavioral, and psychosocial factors and dietary intake among African Americans in North Carolina. J Am Diet Assoc (2005) 1.92
The prostate cancer prevention trial: design, biases and interpretation of study results. J Urol (2006) 1.91
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol (2012) 1.89
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med (2002) 1.85
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. J Nutr (2006) 1.82
Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics (2008) 1.78
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol (2009) 1.73
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2011) 1.71
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials (2004) 1.70
Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer (2003) 1.70
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol (2008) 1.69
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol (2004) 1.68
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst (2014) 1.67
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65